{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:06Z","timestamp":1793963046360,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ygyno.2022.02.010","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T18:00:57Z","timestamp":1646762457000},"page":"385-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Mitigation and management strategies for ocular events associated with tisotumab vedotin"],"prefix":"10.1016","volume":"165","author":[{"given":"Stella K.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ursell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.02.010_bb0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2011-06-317685","article-title":"The relationship between tissue factor and cancer progression: insights from bench and bedside","volume":"119","author":"van den Berg","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2005.05.018","article-title":"Tissue factor and tumor: clinical and laboratory aspects","volume":"364","author":"Forster","year":"2006","journal-title":"Clinica Chimica Acta; Int. J. Clin. Chem."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-11-263","article-title":"Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor","volume":"11","author":"Cocco","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10585-011-9401-0","article-title":"Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor","volume":"28","author":"Cocco","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0040","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0045","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-221","article-title":"Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, fc-mediated, and fab-mediated effector functions in vitro","volume":"79","author":"Alley","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0055","first-page":"63","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"Ando","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0060","first-page":"519","article-title":"Evidence for enhanced tissue factor expression in age-related macular degeneration. Laboratory investigation","volume":"91","author":"Cho","year":"2011","journal-title":"A J. Tech. Meth. Pathol."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0070","series-title":"package insert","author":"Blenrep","year":"2020"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0075","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0080","series-title":"package insert","author":"Tivdak","year":"2021"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0085","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0090","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2016.21038","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0100","first-page":"193","article-title":"Contact lens-related complications: a review","volume":"12","author":"Alipour","year":"2017","journal-title":"J. Ophthal. Vision Res."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0105","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jama.2013.280318","article-title":"Conjunctivitis: a systematic review of diagnosis and treatment","volume":"310","author":"Azari","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0110","doi-asserted-by":"crossref","first-page":"P94","DOI":"10.1016\/j.ophtha.2018.10.020","article-title":"Conjunctivitis preferred practice pattern\u00ae","volume":"126","author":"Varu","year":"2019","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0115","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMra1407936","volume":"378","author":"Clayton","year":"2018","journal-title":"Dry Eye. N Engl J Med."},{"key":"10.1016\/j.ygyno.2022.02.010_bb0120","series-title":"Chapter 5: Cornea. The Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology","first-page":"177","author":"Friedman","year":"2021"},{"key":"10.1016\/j.ygyno.2022.02.010_bb0125","series-title":"Common Terminology Criteria for Adverse Events (CTCAE): Version 5.0","author":"National Cancer Institute","year":"2017"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822001202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822001202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:28Z","timestamp":1758772888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822001202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0090825822001202"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.02.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}